Eli Lilly sheds light on confidential drug pricing, discloses charges for popular diabetes medicine Humalog

25 March 2019 - Eli Lilly says the “net price” for insulin fell to $135 a patient a month in 2018 ...

Read more →

Medicare for all would abolish private insurance. ‘There’s no precedent in American history.’

23 March 2019 - Unlike Obamacare, emerging plans would sweep away the private health insurance system. What would that mean for ...

Read more →

As political scrutiny mounts, Eli Lilly divulges new insulin pricing data

24 March 2019 - Lilly says the price it was paid for popular insulin Humalog fell 8.1% from 2014 to 2018 ...

Read more →

Drug prices on TV? They may be coming.

23 March 2019 - The Trump administration is moving ahead with its proposal to require drug companies to disclose the ...

Read more →

Drug company protections are latest stumbling block for NAFTA rewrite

21 March 2019 - President Trump’s ability to get his revised North American Free Trade Agreement through Congress may hinge ...

Read more →

Senate panel to hear from pharmacy middlemen on drug prices

21 March 2019 - The Senate Finance Committee said Thursday that it has secured commitments from executives of five major ...

Read more →

FDA issues complete response letter for Zynquista (sotagliflozin)

22 March 2019 - The U.S. FDA issued a complete response letter regarding the New Drug Application for investigational Zynquista ...

Read more →

FDA takes new steps to advance natural history studies for accelerating novel treatments for rare diseases

22 March 2019 - The U.S. FDA today issued the draft guidance, Rare Diseases: Natural History Studies for Drug Development.  ...

Read more →

Recro Pharma receives complete response letter from the FDA for intravenous meloxicam

22 March 2019 - Recro Pharma today announced it has received a second complete response letter from the U.S. FDA Office ...

Read more →

Enzyvant's investigational Farber disease enzyme replacement therapy, RVT-801, receives FDA fast track and rare paediatric disease designations

21 March 2019 - Enzyvant today announced that the U.S. FDA has granted are paediatric disease and fast track designations for ...

Read more →

Promoting biosimilars up to health plans, manufacturers, doctors, Gottlieb says

21 March 2019 - As he wraps up his final weeks as commissioner of the FDA, Scott Gottlieb, MD, talked about ...

Read more →

Kentucky launches probe into drug overcharges by pharmacy benefit managers

22 March 2019 - Kentucky Attorney General Andy Beshear said on Thursday he had launched an investigation into allegations that ...

Read more →

Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression

21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...

Read more →

Mystery solved: the pharma-backed group with a lot to say on Trump’s pitch to end drug rebates

20 March 2019 - RetireSafe, a Washington-based advocacy group with ties to the drug industry, appears to be behind a ...

Read more →

FDA approves new device for treating moderate to severe chronic heart failure in patients

21 March 2019 - The U.S. FDA today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure ...

Read more →